# Novartis Pharmaceuticals Corporation - Inspection Records

Source: https://www.keypedia.com/companies/novartis-pharmaceuticals-corporation/aa4c85c1-794a-407a-8eb3-8802c196795b

> Inspection records and compliance data for Novartis Pharmaceuticals Corporation in East Hanover, New Jersey. Access full analysis and detailed observations.

---

## Details

- Name: Novartis Pharmaceuticals Corporation
- FEI Number: 2210396
- City: East Hanover
- State: New Jersey
- Country Name: United States
- Address Line 1: 1 Health Plz
- Zip Code: 07936

## Related Documents

- [FDA Inspection 1276202 - Novartis Pharmaceuticals Corporation - 2025-06-25](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/3303ef9b-e9df-40c1-ae82-b9aa34bb6c57) — source: FDA, date: June 25, 2025
- [FDA Inspection 1276202 - Novartis Pharmaceuticals Corporation - 2025-06-25](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/d76eeb82-f498-4fa6-9c50-25c0625a0d59) — classification: No Action Indicated (NAI), source: FDA, date: June 25, 2025
- [FDA Inspection 1263198 - Novartis Pharmaceuticals Corporation - 2025-03-03](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/ad5f75b3-032d-4614-ab72-4090e385dec1) — source: FDA, date: March 3, 2025
- [FDA Inspection 1263198 - Novartis Pharmaceuticals Corporation - 2025-03-03](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/065307bf-8ec2-419d-a241-59ae20580926) — classification: No Action Indicated (NAI), source: FDA, date: March 3, 2025
- [FDA Inspection 1257911 - Novartis Pharmaceuticals Corporation - 2024-11-19](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/be756448-ed2f-448d-a977-168d3e2f3ff8) — source: FDA, date: November 19, 2024
- [FDA Inspection 1257911 - Novartis Pharmaceuticals Corporation - 2024-11-19](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/74d1a62a-d9e2-4b53-ba1e-0184aaea8099) — classification: No Action Indicated (NAI), source: FDA, date: November 19, 2024
- [FDA Inspection 1248433 - Novartis Pharmaceuticals Corporation - 2024-08-29](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/ccf044c3-0b3e-481e-97b9-66c1a8ca3e62) — classification: No Action Indicated (NAI), source: FDA, date: August 29, 2024
- [FDA Inspection 1230105 - Novartis Pharmaceuticals Corporation - 2024-06-27](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/b5b9853a-4053-4f24-8ef7-e9061d8ecd8a) — classification: No Action Indicated (NAI), source: FDA, date: June 27, 2024
- [483 - Novartis Pharmaceuticals Corporation - 2023-08-21](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/b86a870b-4f00-4ca2-a2ea-f19029e24813) — source: FDA, date: August 21, 2023
- [FDA Inspection 1215374 - Novartis Pharmaceuticals Corporation - 2023-08-21](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/b58d0339-4531-411e-9cc4-b4ca576ddf97) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 21, 2023
- [FDA Inspection 1208424 - Novartis Pharmaceuticals Corporation - 2023-06-13](https://www.keypedia.com/records/fda_inspections/novartis-pharmaceuticals-corporation/fa074e31-283e-4e4d-b21a-e713e7ba0376) — classification: No Action Indicated (NAI), source: FDA, date: June 13, 2023
- [483 - Novartis Pharmaceuticals Corporation - 2018-12-14](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/fbb8db5f-8a5a-4601-9915-315db47dee65) — source: FDA, date: December 14, 2018
- [EIR - Novartis Pharmaceuticals Corporation - 2017-09-07](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/faf8091c-3829-4500-a76d-e0a68515ed42) — source: FDA, date: September 7, 2017
- [EIR - Novartis Pharmaceuticals Corporation - 2017-03-02](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/4b8966de-a19c-48ea-91fb-d06761d6856a) — source: FDA, date: March 2, 2017
- [EIR - Novartis Pharmaceuticals Corporation - 2017-01-24](https://www.keypedia.com/records/eir/novartis-pharmaceuticals-corporation/f6b0814a-9c3b-48e4-a46d-b85c65a0df9e) — source: FDA, date: January 24, 2017
- [483 - Novartis Pharmaceuticals Corporation - 2017-01-24](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/4337d8c5-ec9f-4ec5-9878-9d9925dbaf1b) — source: FDA, date: January 24, 2017
- [483 - Novartis Pharmaceuticals Corporation - 2014-08-05](https://www.keypedia.com/records/483/novartis-pharmaceuticals-corporation/7b7960f8-08c8-49f2-a0bc-275ee2905eaa) — source: FDA, date: August 5, 2014

## Related Companies

- [Nelson Laboratories, LLC](https://www.keypedia.com/companies/nelson-laboratories-llc/978675b0-9c60-4e40-9336-6a71b9f79805)
- [iuvo BioScience Operations, LLC](https://www.keypedia.com/companies/iuvo-bioscience-operations-llc/0d802369-f7b4-423e-8a7c-7a9e2dae4896)
- [Element Materials Technology Midland Inc.](https://www.keypedia.com/companies/element-materials-technology-midland-inc/a0ed9eaa-521f-4bfe-80b2-309354e62271)
- [Pine Lake Investments, Inc.](https://www.keypedia.com/companies/pine-lake-investments-inc/35a10786-69cb-4000-bd35-b63bb921101a)
- [Elemental Analysis, Inc.](https://www.keypedia.com/companies/elemental-analysis-inc/29307a33-c2b2-4ddf-ae7b-7c76e84cfce8)
- [INFINITY-EKG LIFE SCIENCES MO LLC](https://www.keypedia.com/companies/infinity-ekg-life-sciences-mo-llc/bcaf6b67-46e2-4c13-bc55-8107bc325840)
- [Bennett Testing Service, Inc.](https://www.keypedia.com/companies/bennett-testing-service-inc/16765b51-2b93-41db-8c4b-077e856d8dc9)
- [Chromak Research Inc](https://www.keypedia.com/companies/chromak-research-inc/e7eccd52-0e4f-4a4c-81e6-7331d2a64609)
- [Spectral Data Services, Inc.](https://www.keypedia.com/companies/spectral-data-services-inc/d57ed517-a7fb-4a66-8a76-22de97b65f54)
- [Sipra Labs Limited](https://www.keypedia.com/companies/sipra-labs-limited/69207267-fcf6-48c1-a537-2f9bb9497ea6)

## Related Officers

- [investigator](https://www.keypedia.com/people/christina-n-maurino/83a10358-7da6-47e9-8f90-094f81991b86)
- [company_representative](https://www.keypedia.com/people/helen-doster/15c70de3-7324-4908-87f8-a42481682864)
- [company_representative](https://www.keypedia.com/people/john-esposito/30bb5f03-eba4-4bb9-8ced-6177984e15f5)
- [Regulatory Officer](https://www.keypedia.com/people/peter-r-lenahan/c695dac2-5447-434b-801e-f95e6acf05f1)
- [investigator](https://www.keypedia.com/people/nina-yang/8d080437-2e05-4b75-8c53-b818d761cf1f)